Cargando…

Correlation of treatment outcome in sanger/RT-qPCR KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumors with next-generation sequencing results: A single-center report

In patients with gastrointestinal stromal tumors (GIST), it has become mandatory to determine the driver mutation in order to predict the response to standard treatment with tyrosine kinase inhibitors (TKI). A total of 10–15% of all GIST lack activating mutations in KIT proto-oncogene, receptor tyro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Unk, Mojca, Bombač, Alenka, Jezeršek Novaković, Barbara, Stegel, Vida, šetrajčič Dragoš, Vita, Blatnik, Olga, Klančar, Gašper, Novaković, Srdjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351002/ https://www.ncbi.nlm.nih.gov/pubmed/35904169 http://dx.doi.org/10.3892/or.2022.8382

Ejemplares similares

Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours
por: Bombac, Alenka, et al.
Publicado: (2020)

New Approach for Detection of Normal Alternative Splicing Events and Aberrant Spliceogenic Transcripts with Long-Range PCR and Deep RNA Sequencing
por: Dragoš, Vita Šetrajčič, et al.
Publicado: (2021)

Two Novel NF1 Pathogenic Variants Causing the Creation of a New Splice Site in Patients With Neurofibromatosis Type I
por: Setrajcic Dragos, Vita, et al.
Publicado: (2019)

A Novel Germline MLH1 In-Frame Deletion in a Slovenian Lynch Syndrome Family Associated with Uncommon Isolated PMS2 Loss in Tumor Tissue
por: Klančar, Gašper, et al.
Publicado: (2020)

Identification of Spliceogenic Variants beyond Canonical GT-AG Splice Sites in Hereditary Cancer Genes
por: Dragoš, Vita Šetrajčič, et al.
Publicado: (2022)

Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk
por: Strojnik, Ksenija, et al.
Publicado: (2021)

BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome
por: Blatnik, Ana, et al.
Publicado: (2022)

Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing
por: Stegel, Vida, et al.
Publicado: (2022)

Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision
por: Unk, Mojca, et al.
Publicado: (2023)

Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity
por: Cerkovnik, Petra, et al.
Publicado: (2010)

CD56-positive diffuse large B-cell lymphoma: comprehensive analysis of clinical, pathological, and molecular characteristics with literature review
por: Gasljevic, Gorana, et al.
Publicado: (2023)

The Prevalence of Occult Ovarian Cancer in the Series of 155 Consequently Operated High Risk Asymptomatic Patients – Slovenian Population Based Study
por: Gornjec, Andreja, et al.
Publicado: (2020)

KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study
por: Cerne, Jasmina-Ziva, et al.
Publicado: (2012)

Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer
por: Vodusek, Ana Lina, et al.
Publicado: (2011)

Role of specific DNA mutations in the peripheral blood of colorectal cancer patients for the assessment of tumor stage and residual disease following tumor resection
por: Norcic, Gregor, et al.
Publicado: (2016)

An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube
por: Boltežar, Lučka, et al.
Publicado: (2020)

Diagnostic value of immunoglobulin κ light chain gene rearrangement analysis in B-cell lymphomas
por: KOKOVIC, IRA, et al.
Publicado: (2014)

Clonality analysis of lymphoid proliferations using the BIOMED-2 clonality assays: a single institution experience
por: Kokovic, Ira, et al.
Publicado: (2014)

Genetic Counselling, BRCA1/2 Status and Clinico-pathologic Characteristics of Patients with Ovarian Cancer before 50 Years of Age
por: Cvelbar, Mirjam, et al.
Publicado: (2017)

Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
por: Rožman, Samo, et al.
Publicado: (2022)

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
por: ROŽMAN, SAMO, et al.
Publicado: (2016)

Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome
por: Rozman, Samo, et al.
Publicado: (2017)

Correlation of t(14;18) translocation breakpoint site with clinical characteristics in follicular lymphoma
por: Panjan, Matej, et al.
Publicado: (2023)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

Combined effect of CYP1B1, COMT, GSTP1, and MnSOD genotypes and risk of postmenopausal breast cancer
por: Cerne, Jasmina-Ziva, et al.
Publicado: (2011)

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
por: Stegel, Vida, et al.
Publicado: (2011)

Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families
por: NOVAKOVIĆ, SRDJAN, et al.
Publicado: (2012)

Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma
por: Gornjec, Andreja, et al.
Publicado: (2019)

Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma
por: Novakovic, Aleksander, et al.
Publicado: (2020)

Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
por: Jezeršek Novaković, Barbara, et al.
Publicado: (2021)

Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 – a single centre report
por: Jezersek Novakovic, Barbara
Publicado: (2012)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
por: Novakovic, Barbara Jezersek
Publicado: (2015)

Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
por: Horvat, Matej, et al.
Publicado: (2018)

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient
por: Negri, T, et al.
Publicado: (2007)

Data on quantification of signaling pathways activated by KIT and PDGFRA mutants
por: Bahlawane, Christelle, et al.
Publicado: (2016)

Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour
por: Priya, Valli, et al.
Publicado: (2020)

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma
por: Horvat, Mateja, et al.
Publicado: (2010)

NUT Carcinoma: A Clinical, Morphological and Immunohistochemical Mimicker—The Role of RNA Sequencing in the Diagnostic Procedure
por: Gasljevic, Gorana, et al.
Publicado: (2021)

Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma
por: Moltara, Maja Ebert, et al.
Publicado: (2018)

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
por: Lassus, H, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_3mef07tb3gdcmqsc9saajdvhpt